CN113466150A - Serum sodium detection reagent freeze-dried microsphere and preparation method thereof - Google Patents
Serum sodium detection reagent freeze-dried microsphere and preparation method thereof Download PDFInfo
- Publication number
- CN113466150A CN113466150A CN202110736048.9A CN202110736048A CN113466150A CN 113466150 A CN113466150 A CN 113466150A CN 202110736048 A CN202110736048 A CN 202110736048A CN 113466150 A CN113466150 A CN 113466150A
- Authority
- CN
- China
- Prior art keywords
- freeze
- detection reagent
- detection
- drying
- serum sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 103
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 75
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 52
- 210000002966 serum Anatomy 0.000 title claims abstract description 52
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 52
- 239000011734 sodium Substances 0.000 title claims abstract description 52
- 239000004005 microsphere Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000004108 freeze drying Methods 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 239000000758 substrate Substances 0.000 claims abstract description 21
- 239000003755 preservative agent Substances 0.000 claims abstract description 14
- 230000002335 preservative effect Effects 0.000 claims abstract description 13
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000007983 Tris buffer Substances 0.000 claims abstract description 9
- 238000004458 analytical method Methods 0.000 claims abstract description 9
- 239000003223 protective agent Substances 0.000 claims abstract description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 102000005936 beta-Galactosidase Human genes 0.000 claims abstract description 7
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 claims abstract 2
- 238000001035 drying Methods 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 238000000859 sublimation Methods 0.000 claims description 12
- 230000008022 sublimation Effects 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 claims description 7
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- -1 Tween-40 Polymers 0.000 claims description 4
- 150000003983 crown ethers Chemical class 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000003795 desorption Methods 0.000 claims description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 3
- 229940033663 thimerosal Drugs 0.000 claims description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 239000004283 Sodium sorbate Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 claims description 2
- 235000019250 sodium sorbate Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 230000008569 process Effects 0.000 abstract description 8
- 229910001415 sodium ion Inorganic materials 0.000 abstract description 7
- 239000011324 bead Substances 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000012123 point-of-care testing Methods 0.000 abstract description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 206010021036 Hyponatraemia Diseases 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000005048 flame photometry Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
Abstract
The invention relates to the field of preparation of detection reagents, and discloses a serum sodium detection reagent freeze-dried microsphere which is formed by freeze-drying a detection reagent, wherein the detection reagent comprises the following components: 100-1000 mmol/L Tris buffer solution, 1-5 KU/L, ONPG 5-20 mmol/L beta-galactosidase, 10-200 mmol/L hole-mixing agent, 0.5-2% substrate protective agent, 0.1-1% surfactant, 0.05-0.5% freeze-drying stabilizer and 0.01-0.1% preservative. After the detection reagent is prepared, carrying out liquid separation on the beads to form microspheres, and then carrying out freeze drying to form freeze-dried microspheres. During detection, a biochemical analyzer is adopted, and a two-point velocity method is used for detection, wherein the main wavelength of the detection is 405nm, and the auxiliary wavelength of the detection is 660 nm. The invention greatly simplifies the operation process, avoids the pollution possibility, enhances the stability and the anti-interference capability of the reagent, is suitable for automatic analysis in hospitals and medical institutions, and is a feasible POCT new method for detecting serum sodium ions.
Description
Technical Field
The invention relates to the field of detection reagent preparation, in particular to a serum sodium detection reagent freeze-dried microsphere and a preparation method thereof.
Background
Sodium ions are important electrolytes in extracellular fluid, are the most cations in extracellular fluid such as blood, have important significance in maintaining the capacity of the extracellular fluid, regulating acid-base balance, maintaining normal osmotic pressure and cell physiological functions, and participate in maintaining normal stress of nerve-muscle. The total sodium (sodium) in human body is 60-100 g, and average 45-50 mmol/kg, wherein 44% exists in extracellular fluid, 47% exists in bone, and about 10% exists in intracellular fluid. The normal blood sodium value is 135-145mmol/L, and the blood sodium value lower than 135mmol/L is hyponatremia. Hyponatremia can present as a series of clinical symptoms, most commonly electrolyte disturbances. Acute hyponatremia can be life threatening, the fatality rate can reach 30% when the blood sodium is lower than 120mmol/L, and the fatality rate of patients can reach 40% when the blood sodium is lower than 114 mmol/L.
At present, the main methods for detecting sodium ions include: flame photometry, ion selective electrode method (ISE), enzymatic methods, radionuclide dilution-mass spectrometry (ID-ms), and neutron activation. The more common methods used clinically to measure sodium are ion selective electrode assay (ISE) and enzymatic methods. The ISE method has the advantages of small sample consumption, capability of being combined with an automatic biochemical analyzer, rapidness, accuracy, good repeatability, strong specificity, simplicity and convenience in operation and the like, but the electrode has a certain service life, and is aged and needs to be replaced periodically after being used for a period of time. The flame photometry is a reference method for sodium determination, has accurate result and has the defects that the dilution factor of a sample is large, and combustible gas is used, so that potential safety hazard exists. The precision and accuracy of the enzyme method can be close to those of a flame photometric method, the defect that a biochemical analyzer cannot directly measure sodium ions is overcome, and the method has the advantages of simplicity, accuracy, good repeatability, strong specificity, small serum dosage and the like, but the method is poor in stability, difficult to store and transport (generally requiring dry ice transportation) and detect beside a bed, easy to be interfered by external environments (temperature and pH value) and the like. Therefore, the development of a timely detection method for serum sodium, which has good stability, strong specificity and simple operation, is urgently needed.
Disclosure of Invention
The invention aims to provide a serum sodium detection reagent freeze-dried microsphere with good stability, strong specificity and simple and convenient operation and a preparation method thereof, so as to solve the problems of complex operation, high cost and difficult carrying of the detection method in the prior art.
In order to achieve the purpose, the invention adopts the following technical scheme: a serum sodium detection reagent freeze-dried microsphere is formed by freeze-drying a detection reagent, and the detection reagent comprises the following components: 100-1000 mmol/L Tris buffer solution, 1-5 KU/L, ONPG 5-20 mmol/L beta-galactosidase, 10-200 mmol/L hole-mixing agent, 0.5-2% substrate protective agent, 0.1-1% surfactant, 0.05-0.5% freeze-drying stabilizer and 0.01-0.1% preservative. The preparation method of the serum sodium detection reagent freeze-dried microspheres comprises the following steps: preparing a detection reagent; dripping the detection reagent into liquid nitrogen to obtain microspheres; freeze-drying the microspheres to form freeze-dried microspheres; during detection, a biochemical analyzer is adopted, and a two-point velocity method is used for detection, wherein the main wavelength of the detection is 405nm, and the auxiliary wavelength of the detection is 660 nm.
The principle and the advantages of the scheme are as follows: in practical application, the technical scheme optimizes a reaction system on the basis of a pyruvic acid kinase method, and prepares the single-reagent freeze-dried microspheres by adding the substrate protective agent and the freeze-drying stabilizer, wherein the freeze-dried microspheres can be stored at the temperature of 2-8 ℃ or room temperature for a long time without affecting the performance, the storage and transportation requirements and the cost of the conventional serum sodium detection reagent are greatly reduced, and the use convenience of the reagent is improved. The stability and the anti-interference capability of the reagent can be obviously improved by adding the substrate protective agent and the freeze-drying stabilizer. By adding the surfactant, the reaction system can be prevented from being turbid, the stability of the substrate is enhanced, and the aim of further enhancing the anti-interference capability is fulfilled.
The method is characterized in that o-nitrophenol-beta-D-galactoside (ONPG) is utilized to generate o-nitrophenol (ONP) and galactose under the catalysis of sodium-dependent beta-D-galactoside, and the generation amount of the o-nitrophenol (ONP) is in direct proportion to the concentration of sodium ions in a sample. In addition, according to the characteristic that ortho-nitrophenol (ONP) is yellow in an alkaline environment, the rising speed of absorbance at a wavelength of 405nm can be monitored during detection, so that the concentration of sodium ions can be calculated. The invention greatly simplifies the operation process, avoids the pollution possibility, enhances the stability and the anti-interference capability of the reagent, is suitable for automatic analysis in hospitals and medical institutions, and is a feasible POCT new method for detecting serum sodium ions.
Preferably, as an improvement, the substrate protective agent is one or more of PEG4000, PEG8000, PEG20000 or polyethylene glycol.
In the technical scheme, the substrate protective agent can improve the stability of the substrate, maintain the sensitivity of the substrate and improve the anti-interference capability of the substrate. Experiments prove that the substrate protective agent can achieve better effect. When PEG8000 and PEG20000 are combined for use, the mass ratio of the two is 1: 2.
preferably, as a modification, the freeze-drying stabilizer is one or more of trehalose, sucrose, lactose or BSA.
In the technical scheme, the freeze-drying stabilizer can improve the stability of the detection reagent in the freeze-drying process, increase the content of dry substances and enable the freeze-dried product to form ideal blocks.
Preferably, as an improvement, the cryptate is cryptate or crown ether.
In the technical scheme, the polycycle ligand of the hole mixture agent is a coordination compound which is formed by pertinently combining with certain metal ions. In alkali metal ions, the binding capacity of the metal ion is strong, the hole mixture can reduce the concentration of free metal ions, eliminate the interference of the metal ions on detection, and further ensure the accuracy of detection results.
Preferably, as an improvement, the surfactant is one or more of tween-20, tween-40, tween-80, BC30TX, triton x-100 or polyoxyethylene lauryl ether Brij 35.
In the technical scheme, the surfactant has the functions of emulsifying and increasing hydrophilicity, and has the functions of improving solubility and renaturation of antigens, so that the specific recognition capability can be improved. The surfactant is the best choice after experimental verification.
Preferably, as an improvement, the preservative is one of sodium azide, thimerosal, sodium sorbate and Proclin preservative.
In the technical scheme, the preservative has the function of inhibiting the growth of bacteria, can prolong the effective period of the reagent and has no influence on the reagent. The selection of the preservative mainly considers the influence of toxicity on the environment, because sodium azide and thimerosal have the characteristic of good broad spectrum, but have toxicity (to human and environment), so the Proclin series of biological preservatives are mostly used at present.
Preferably, as an improvement, the pH of the Tris buffer is 8.0-9.0.
In the technical scheme, the pH of the buffer solution is optimized, so that the whole detection reagent system is in alkalescence, basic conditions are created for the color development of ortho-nitrophenol (ONP), and the subsequent detection is facilitated.
Preferably, as an improvement, after the preparation of the detection reagent is completed, the detection reagent is subjected to liquid separation and bead formation to form microspheres, and then freeze drying is performed to form freeze-dried microspheres.
Preferably, as an improvement, the freeze-drying comprises a prefreezing stage, a sublimation drying stage and a desorption drying stage, and the prefreezing stage is carried out under the following conditions: 60min at-50 ℃; the conditions of drying in the sublimation drying stage are: 60min at-30 ℃; 60min at-20 ℃; 60min at-10 ℃; sequentially carrying out the steps at 0 ℃ for 60 min; the conditions in the desorption drying stage were: 10 ℃ for 60 min; sequentially at 20 deg.C for 60 min.
In the technical scheme, the freeze-drying process is mainly a freeze-drying microsphere forming process, and the freeze-drying conditions are optimized, so that the freeze-drying uniformity of the freeze-drying microspheres can be ensured, and the quick balling of the freeze-drying microspheres is facilitated.
Drawings
FIG. 1 is a morphological diagram of lyophilized microspheres of the serum sodium detection reagent of the present invention.
FIG. 2 is a line graph of the serum sodium detection reagent of example 1 of the present invention.
FIG. 3 is a line graph of the serum sodium detection reagent of example 2 of the present invention.
FIG. 4 is a line graph of the serum sodium detection reagent of example 3 of the present invention.
FIG. 5 is a line graph of the serum sodium detection reagent of example 4 of the present invention.
Detailed Description
The following is further detailed by way of specific embodiments:
example 1
A preparation method of lyophilized microspheres of a serum sodium detection reagent comprises the following steps:
s1: the serum sodium detection reagent in the embodiment is prepared by the following components:
TABLE 1
| Components | Specific components | Concentration of |
| Buffer solution | Tris(pH 9.0) | 500mmol/L |
| Beta-galactosidase | Beta-galactosidase | 1KU/L |
| ONPG | ONPG | 7mmol/L |
| Acupoint mixture | K221 | 15mmol/L |
| Substrate protectant | PEG20000 | 2％ |
| Substrate protectant | PEG8000 | 1％ |
| Surface active agent | TritonX-100 | 0.1％ |
| Freeze-drying stabilizer | Trehalose | 0.05％ |
| Preservative | Proclin-300 | 0.01％ |
And uniformly mixing the raw materials in proportion to obtain the serum sodium detection reagent.
S2: preparing freeze-dried microspheres, namely separating liquid drop beads (3 ul/drop) of the prepared serum sodium detection reagent in liquid nitrogen by using an automatic liquid separation system, forming the microspheres in the liquid nitrogen by using the detection reagent as shown in figure 1, and performing freeze-drying treatment in a freeze dryer, wherein the freeze-drying in the embodiment comprises a pre-freezing stage, a sublimation drying stage and an analysis drying stage, and the pre-freezing stage comprises the following steps: 60min at-50 ℃; a sublimation drying stage: 60min at-30 ℃; 60min at-20 ℃; 60min at-10 ℃; sequentially carrying out the steps at 0 ℃ for 60 min; and (3) analysis and drying stage: 10 ℃ for 60 min; sequentially at 20 deg.C for 60 min.
And (3) detection procedures:
during actual detection, a biochemical analyzer is adopted, a two-point speed method is used for detection, the main wavelength of detection is 405nm, the sub-wavelength of detection is 660nm, the detection temperature is 37 ℃, and the cuvette is 100 ul.
A blank control group, a standard group and a sample group are respectively set, wherein the standard is Landau calibration serum cal2351-1028UE, the sample is a self-made sample (matrix serum plus sodium chloride), and the setting of each treatment group is as follows:
TABLE 2
| Treatment group | Ultrapure water | Standard article | Sample(s) | Detection reagent freeze-dried microsphere |
| Blank group | 20ul | / | / | 3 ul/piece |
| Standard substance group | / | 20ul | / | 3 ul/piece |
| Sample set | / | / | 20ul | 3 ul/piece |
Mixing the above treatment groups, incubating at 37 deg.C for 1min, and reading A1; read A2 after 5 min. The absorbance change Δ a ═ a1-a 2.
And (4) calculating a result: serum sodium concentration (mmol/L) ═ Δ AMeasurement/min/ΔAStandard/minConcentration of standard sodium salt solution (mmol/L)
The results are shown in fig. 2, and verification proves that the freeze-dried microspheres of the embodiment have good comparative correlation with the similar liquid detection double reagents, and R is20.9873, the clinical results were consistent and the stability and duration were better.
Example 2
The preparation method of the serum sodium detection reagent freeze-dried microspheres comprises the following steps:
s1: the serum sodium detection reagent in the embodiment is prepared by the following components:
TABLE 3
| Components | Specific components | Concentration of |
| Buffer solution | Tris(pH 9.0) | 500mmol/L |
| Beta-galactosidase | Beta-galactosidase | 1KU/L |
| ONPG | ONPG | 7mmol/L |
| Acupoint mixture | K221 | 15mmol/L |
| Substrate protectant | PEG20000 | 2％ |
| Substrate protectant | PEG8000 | 1％ |
| Surface active agent | TritonX-100 | 0.1％ |
| Freeze-drying stabilizer | Trehalose | 0.05％ |
| Preservative | Proclin-300 | 0.01％ |
And uniformly mixing the raw materials in proportion to obtain the serum sodium detection reagent.
S2: the preparation of freeze-dried microsphere, utilize automatic liquid distribution system to carry out liquid distribution drop pearl (5 ul/drop) in liquid nitrogen with the serum sodium detect reagent who prepares, detect reagent forms the microsphere in liquid nitrogen, carries out freeze-drying process in the freeze-drying machine again, and freeze-drying includes prefreezing stage, sublimation drying stage and analysis drying stage in this embodiment, prefreezes: 60min at-50 ℃; sublimation drying: 60min at-30 ℃; 60min at-20 ℃; 60min at-10 ℃; sequentially carrying out the steps at 0 ℃ for 60 min; and (3) resolving and drying: 10 ℃ for 60 min; sequentially at 20 deg.C for 60 min.
And (3) detection procedures:
during actual detection, a biochemical analyzer is adopted, a two-point speed method is used for detection, the main wavelength of detection is 405nm, the sub-wavelength of detection is 660nm, the detection temperature is 37 ℃, and the cuvette is 100 ul.
A blank control group, a standard group and a sample group are respectively set, wherein the standard is Landau calibration serum cal2351-1028UE, the sample is a self-made sample (matrix serum plus sodium chloride), and the setting of each treatment group is as follows:
TABLE 4
| Treatment group | Ultrapure water | Standard article | Sample(s) | Detection reagent freeze-dried microsphere |
| Blank group | 20ul | / | / | 5 ul/piece |
| Standard substance group | / | 20ul | / | 5 ul/piece |
| Sample set | / | / | 20ul | 5 ul/piece |
Mixing the above treatment groups, incubating at 37 deg.C for 1min, and reading A1; read A2 after 5 min. The absorbance change Δ a ═ a1-a 2.
And (4) calculating a result: serum sodium concentration (mmol/L) ═ Δ AMeasurement/min/ΔAStandard/minConcentration of standard sodium salt solution (mmol/L)
The results are shown in fig. 3, and verification proves that the freeze-dried microspheres of the embodiment have good comparative correlation with the similar liquid detection double reagents, and R is20.9887, the clinical results were consistent and the stability and duration were better.
Example 3
The preparation method of the serum sodium detection reagent freeze-dried microspheres comprises the following steps:
s1: the serum sodium detection reagent in the embodiment is prepared by the following components:
TABLE 5
| Components | Specific components | Concentration of |
| Buffer solution | Tris(pH 9.0) | 500mmol/L |
| Beta-galactosidase | Beta-galactosidase enzyme | 1KU/L |
| ONPG | ONPG | 7mmol/L |
| Acupoint mixture | Crown ethers | 100mmol/L |
| Substrate protectant | PEG20000 | 2％ |
| Substrate protectant | PEG8000 | 1％ |
| Surface active agent | TritonX-100 | 0.1％ |
| Freeze-drying stabilizer | Trehalose | 0.05％ |
| Preservative | Proclin-300 | 0.01％ |
And uniformly mixing the raw materials in proportion to obtain the serum sodium detection reagent.
S2: the preparation of freeze-dried microsphere, utilize automatic liquid distribution system to carry out liquid distribution drop pearl (5 ul/drop) in liquid nitrogen with the serum sodium detect reagent who prepares, detect reagent forms the microsphere in liquid nitrogen, carries out freeze-drying process in the freeze-drying machine again, and freeze-drying includes prefreezing stage, sublimation drying stage and analysis drying stage in this embodiment, prefreezes: 60min at-50 ℃; sublimation drying: 60min at-30 ℃; 60min at-20 ℃; 60min at-10 ℃; sequentially carrying out the steps at 0 ℃ for 60 min; and (3) resolving and drying: 10 ℃ for 60 min; sequentially at 20 deg.C for 60 min.
And (3) detection procedures:
during actual detection, a biochemical analyzer is adopted, a two-point speed method is used for detection, the main wavelength of detection is 405nm, the sub-wavelength of detection is 660nm, the detection temperature is 37 ℃, and the cuvette is 100 ul.
A blank control group, a standard substance group and a sample group are respectively set, and the setting of each treatment group is as follows:
TABLE 6
| Treatment group | Ultrapure water | Standard article | Sample(s) | Detection reagent freeze-dried microsphere |
| Blank group | 20ul | / | / | 5 ul/piece |
| Standard substance group | / | 20ul | / | 5 ul/piece |
| Sample set | / | / | 20ul | 5 ul/piece |
Mixing the above treatment groups, incubating at 37 deg.C for 1min, and reading A1; read A2 after 5 min. The absorbance change Δ a ═ a1-a 2.
And (4) calculating a result: serum sodium concentration (mmol/L) ═ Δ AMeasurement/min/ΔAStandard/minConcentration of standard sodium salt solution (mmol/L)
The results are shown in fig. 4, and verification proves that the freeze-dried microspheres of the embodiment have good comparative correlation with the similar liquid detection double reagents, and R is20.9893, the clinical results were consistent and the stability and duration were better.
Example 4
The preparation method of the serum sodium detection reagent freeze-dried microspheres comprises the following steps:
s1: the serum sodium detection reagent in the embodiment is prepared by the following components:
TABLE 7
| Components | Specific components | Concentration of |
| BufferLiquid for treating urinary tract infection | Tris(pH 9.0) | 500mmol/L |
| Beta-galactosidase | Beta-galactosidase enzyme | 1KU/L |
| ONPG | ONPG | 7mmol/L |
| Acupoint mixture | Crown ethers | 100mmol/L |
| Substrate protectant | PEG20000 | 2％ |
| Substrate protectant | PEG8000 | 1％ |
| Surface active agent | TritonX-100 | 0.1％ |
| Freeze-drying stabilizer | Trehalose | 0.05％ |
| Preservative | Proclin-300 | 0.01％ |
And uniformly mixing the raw materials in proportion to obtain the serum sodium detection reagent.
S2: the preparation of freeze-drying microballon, utilize automatic liquid distribution system to carry out liquid distribution dripping pearl (5 ul/drop) in liquid nitrogen with the serum sodium detect reagent who prepares, detect reagent forms the microballon in liquid nitrogen, carries out freeze-drying process in the freeze-drying machine again, and freeze-drying includes prefreezing stage, sublimation drying stage and analysis drying stage in this embodiment, prefreezing stage: 60min at-50 ℃; a sublimation drying stage: 60min at-30 ℃; 60min at-20 ℃; 60min at-10 ℃; sequentially carrying out the steps at 0 ℃ for 60 min; and (3) analysis and drying stage: 10 ℃ for 60 min; sequentially at 20 deg.C for 60 min.
And (3) detection procedures:
during actual detection, a biochemical analyzer is adopted, a two-point speed method is used for detection, the main wavelength of detection is 405nm, the sub-wavelength of detection is 660nm, the detection temperature is 37 ℃, and the cuvette is 100 ul.
A blank control group, a standard substance group and a sample group are respectively set, and the setting of each treatment group is as follows:
TABLE 8
| Treatment group | Ultrapure water | Standard article | Sample(s) | Detection reagent freeze-dried microsphere |
| Blank group | 20ul | / | / | 10 ul/piece |
| Standard substance group | / | 20ul | / | 10 ul/piece |
| Sample set | / | / | 20ul | 10 ul/piece |
Mixing the above treatment groups, incubating at 37 deg.C for 1min, and reading A1; read A2 after 5 min. The absorbance change Δ a ═ a1-a 2.
And (4) calculating a result: serum sodium concentration (mmol/L) ═ Δ AMeasurement/min/ΔAStandard/minConcentration of standard sodium salt solution (mmol/L)
The results are shown in fig. 5, and verification proves that the freeze-dried microspheres of the embodiment have good comparative correlation with the similar liquid detection double reagents, and R is20.9978, the clinical results were consistent and the stability and duration were better.
The foregoing is merely an example of the present invention and common general knowledge in the art of designing and/or characterizing particular aspects and/or features is not described in any greater detail herein. It should be noted that, for those skilled in the art, without departing from the technical solution of the present invention, several variations and modifications can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicability of the patent. The scope of the claims of the present application shall be determined by the contents of the claims, and the description of the embodiments and the like in the specification shall be used to explain the contents of the claims.
Claims (10)
1. The serum sodium detection reagent freeze-dried microsphere is characterized by being formed by freeze-drying a detection reagent, wherein the detection reagent comprises the following components: 100-1000 mmol/L Tris buffer solution, 1-5 KU/L, ONPG 5-20 mmol/L beta-galactosidase, 10-200 mmol/L hole-mixing agent, 0.5-2% substrate protective agent, 0.1-1% surfactant, 0.05-0.5% freeze-drying stabilizer and 0.01-0.1% preservative.
2. The lyophilized microsphere for serum sodium detection reagent according to claim 1, wherein: the substrate protective agent is one or more of PEG4000, PEG8000, PEG20000 or polyethylene glycol.
3. The lyophilized microsphere for serum sodium detection reagent according to claim 2, wherein: the freeze-drying stabilizer is one or more of trehalose, sucrose, lactose or BSA.
4. The lyophilized microsphere for serum sodium detection reagent according to claim 3, wherein: the acupoint mixture is acupoint ether or crown ether.
5. The lyophilized microsphere for serum sodium detection reagent according to claim 4, wherein: the surfactant is one or more of Tween-20, Tween-40, Tween-80, BC30TX, TritonX-100 or polyoxyethylene lauryl ether Brij 35.
6. The lyophilized microsphere for serum sodium detection reagent according to claim 5, wherein: the preservative is one of sodium azide, thimerosal, sodium sorbate and Proclin preservative.
7. The lyophilized microsphere for serum sodium detection reagent according to claim 6, wherein: the pH value of the Tris buffer solution is 8.0-9.0.
8. A preparation method of serum sodium detection reagent freeze-dried microspheres is characterized by comprising the following steps: preparing a detection reagent; dripping the detection reagent into liquid nitrogen to obtain microspheres; freeze drying the microspheres to form freeze dried microspheres.
9. The method for preparing the lyophilized microsphere for sodium serum detection reagent according to claim 8, wherein the method comprises the following steps: the freeze drying comprises a pre-freezing stage, a sublimation drying stage and an analysis drying stage, wherein the conditions of the pre-freezing stage are as follows: 60min at-50 ℃; the conditions of drying in the sublimation drying stage are: 60min at-30 ℃; 60min at-20 ℃; 60min at-10 ℃; sequentially carrying out the steps at 0 ℃ for 60 min; the conditions in the desorption drying stage were: 10 ℃ for 60 min; sequentially at 20 deg.C for 60 min.
10. A method for detecting serum sodium by using a serum sodium detection reagent freeze-dried microsphere is characterized by comprising the following steps: and a biochemical analyzer is adopted, and a two-point velocity method is utilized for detection, wherein the main wavelength of the detection is 405nm, and the auxiliary wavelength of the detection is 660 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110736048.9A CN113466150A (en) | 2021-06-30 | 2021-06-30 | Serum sodium detection reagent freeze-dried microsphere and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110736048.9A CN113466150A (en) | 2021-06-30 | 2021-06-30 | Serum sodium detection reagent freeze-dried microsphere and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113466150A true CN113466150A (en) | 2021-10-01 |
Family
ID=77876453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110736048.9A Pending CN113466150A (en) | 2021-06-30 | 2021-06-30 | Serum sodium detection reagent freeze-dried microsphere and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113466150A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101698880A (en) * | 2009-09-08 | 2010-04-28 | 北京利德曼生化股份有限公司 | Quantitative determination kit for serum sodium ion by enzymatic method and preparation and detection method thereof |
| CN104215753A (en) * | 2014-08-30 | 2014-12-17 | 中国科学院苏州生物医学工程技术研究所 | Reagent freeze-dried microsphere for detecting concentrated carbon dioxide binding force and preparation method of reagent freeze-dried microsphere |
| CN110452972A (en) * | 2018-05-08 | 2019-11-15 | 北京中科生仪科技有限公司 | A kind of freeze-drying microballoon of nucleic acid amplification reaction reagent and preparation method thereof |
| CN110779971A (en) * | 2019-09-24 | 2020-02-11 | 重庆东渝中能实业有限公司 | Sample treatment fluid for trace vitamin A detection and electrochemical detection method thereof |
| CN113278676A (en) * | 2021-04-23 | 2021-08-20 | 深圳市锦瑞生物科技有限公司 | Serum sodium detection reagent and gamma-glutamyl transferase detection reagent |
-
2021
- 2021-06-30 CN CN202110736048.9A patent/CN113466150A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101698880A (en) * | 2009-09-08 | 2010-04-28 | 北京利德曼生化股份有限公司 | Quantitative determination kit for serum sodium ion by enzymatic method and preparation and detection method thereof |
| CN104215753A (en) * | 2014-08-30 | 2014-12-17 | 中国科学院苏州生物医学工程技术研究所 | Reagent freeze-dried microsphere for detecting concentrated carbon dioxide binding force and preparation method of reagent freeze-dried microsphere |
| CN110452972A (en) * | 2018-05-08 | 2019-11-15 | 北京中科生仪科技有限公司 | A kind of freeze-drying microballoon of nucleic acid amplification reaction reagent and preparation method thereof |
| CN110779971A (en) * | 2019-09-24 | 2020-02-11 | 重庆东渝中能实业有限公司 | Sample treatment fluid for trace vitamin A detection and electrochemical detection method thereof |
| CN113278676A (en) * | 2021-04-23 | 2021-08-20 | 深圳市锦瑞生物科技有限公司 | Serum sodium detection reagent and gamma-glutamyl transferase detection reagent |
Non-Patent Citations (7)
| Title |
|---|
| 吴杰红等: "干化学法检测钠离子的实验研究", 《国际检验医学杂志》 * |
| 李诗雨: "免标记的G-四链体荧光传感器的构建及对DNA和miRNA的研究", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技Ⅰ辑》 * |
| 杜芳 等: "云芝发酵液中α-半乳糖苷酶酶学特性的研究", 《中国食用菌》 * |
| 沈鸿雁等: "非水介质中酶催化反应研究新进展", 《有机化学》 * |
| 王娜等: "三氯化铝浸取-火焰原子吸收光谱法测定水系沉积物中低含量的碳酸铁", 《岩矿测试》 * |
| 罗满林: "《兽医生物制品学》", 30 April 2019, 中国农业大学出版社 * |
| 高原叶 等: "《实用临床检验医学》", 31 March 2019, 吉林科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Werner et al. | Simultaneous determination of neopterin and creatinine in serum with solid-phase extraction and on-line elution liquid chromatography. | |
| CN101059521B (en) | Reagent for determining fibrinogen content without need of diluting plasma sample and the determination method | |
| CN111638106A (en) | Dry chemical analysis quality control substance for urine | |
| CN112526134A (en) | Chitinase 3-like protein 1 determination kit | |
| CN107727869A (en) | Kit of antinuclear antibodies and preparation method thereof in a kind of measure serum | |
| CN105954453A (en) | Kit for simultaneously quantifying and detecting niacin, nicotinamide and pantothenic acid | |
| CN111948153A (en) | Freeze-drying reagent ball, biochemical analysis chip and serum total calcium determination method | |
| Fossati et al. | A step forward in enzymatic measurement of creatinine | |
| CN109725162A (en) | A kind of detection kit and its method of complete homogeneous determination insulin | |
| CN108872220B (en) | Mercury-free p-hydroxyphenylalanine detection reagent and preparation method and application thereof | |
| CN106868096A (en) | A kind of stability is strong and hexokinase method glucose determination reagent of low cost | |
| CN112710853B (en) | Anti-interference and stable serum direct bilirubin (enzyme method) determination kit and preparation method and application thereof | |
| CN114200122A (en) | Freeze-dried reagent ball for uric acid detection, configuration method thereof and microfluidic detection chip | |
| CN113466150A (en) | Serum sodium detection reagent freeze-dried microsphere and preparation method thereof | |
| CN102564979A (en) | Method for determining alcohol concentration by using enzyme cycling method and alcohol determination kit | |
| Kuan et al. | Enzymatic determination of serum urea on the surface of silicone-rubber pads | |
| CN100494994C (en) | Analysis method for detecting activity of nitrous acid reductase in soil | |
| CN113514451B (en) | Blood creatinine detection reagent ball and blood creatinine detection chip | |
| CN114875114A (en) | Soluble fms-like tyrosine kinase-1 quality control product and preparation method thereof | |
| Asp | Improved method for the assay of phenylglycosidase activity with a 4-aminoantipyrine reagent | |
| CN113655006A (en) | Urinary system calculus stone forming risk factor detection and test system | |
| CN113466151A (en) | Serum potassium detection reagent freeze-dried microsphere and preparation method thereof | |
| CN111579690A (en) | Mass spectrum detection reagent for determining mycophenolic acid content in biological sample by using mycophenolic acid-D3 as internal standard substance and using method thereof | |
| Mandels et al. | Constitutive and induced trehalose transport mechanisms in spores of the fungus Myrothecium verrucaria | |
| JP5425062B2 (en) | Method for measuring glycoalbumin and the like using a control sample containing D-mannitol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211001 |
|
| RJ01 | Rejection of invention patent application after publication |